Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
|Articles|March 27, 2018
Secondary Packaging for Injectables
Packaging systems for injectable pharmaceutical products from Keystone Folding Box include paperboard and plastic-hybrid designs.
Keystone Folding Box Co., a designer and cGMP manufacturer of paperboard packaging solutions, has introduced a line of secondary packaging systems for injectable pharmaceutical products. The products are available in custom all-paperboard and plastic-hybrid designs for prefilled syringes, auto-injector pens, vials, and ampoules, as well as combinations of these.
The systems are suitable for automated or manual production for clinical trials or full-scale commercial production. Packaging materials are compatible with low-temperature exposure, making them appropriate for typical temperatures associated with the cold-chain distribution of injectable products.
The collection includes the Vial Pack line of cartons for packaging single or multiple vials or ampoules; Injectable Packs suitable for prefilled syringes or auto-injector pens, which can be designed to include ancillary items such as sterile wipes; and the InjectaSlide package, which includes a thermoformed tray that slides inside a carton and into a locked position. The locking function is enabled by a lock-release button that must be pressed to unlock and slide the tray forward for access to each dose. Additional features include child-resistant functions for several of the products and dosage-scheduling functions for in-home use of multi-dose packs, which can remind patients to administer the correct dose at the proper date and time.
Source:
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.